This issue showcases strategies that organizations are adopting to stay competitive as pressing industry trends shape the ...

AstraZeneca’s $4.5 billion investment in Virginia expands its US drug manufacturing footprint, creating 3600 jobs and ...

Digitalization and automation enhance aseptic processing by improving speed, repeatability, and quality, with recipe-driven ...

At the Cell and Gene Meeting on the Mesa, a panel discussion was held on advanced therapy production and how it demands ...

The awarded $1.7 million in funding will support the company’s preclinical and clinical progress on DMX-1001 (noribogaine), ...

In the conclusion of this three-part series, the author explores the potential use of agentic AI in pharmaceutical R&D.

Siegfried Schmitt, PhD, vice-president, Technical at Parexel, answers questions on the use and benefits of real-world ...

EMA's draft reflection paper promotes using patient experience data in drug regulation to enhance decision-making processes.

Sept. 30 marked 61 days since July 31, one day past the timeframe President Donald Trump had set forth for companies to lower ...

US President Donald Trump was due to make an announcement that a source said would confirm AstraZeneca as the second of 17 major pharmaceutical companies, after Pfizer, to agree to most-favored-nation ...

The new label for prefilled syringes, in conjunction with innovations from SCHOTT Pharma, enables integrated tamper-evidence ...

The licensing of Talicia, an FDA-approved fixed-dose therapy, to key at-risk markets strategically combats an increasingly ...